Lexaria Bioscience Corp (LEXX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.35M
Last updated: Nov 17, 2026 at 4:10 PM ET
Lexaria Bioscience Corp (LEXX) Statistics
Lexaria Bioscience (LEXX) has a market cap of $9.35M. It kept -3985.58% of revenue as net income over the last 12 months. Its share count is up 35.56% from a year earlier.
Total Valuation
| Market Cap | $9.35M |
|---|---|
| Latest price (Nov 17, 2026) | $4.18 |
Key Dates
The next earnings report is expected on Nov 26, 2026, covering the quarter ending Aug 31, 2026.
| Next Earnings Date | Nov 26, 2026 (expected) |
|---|---|
| Last Earnings Date | Jul 13, 2026 |
| Fiscal Year End | August |
Valuation Ratios
Sales and book value multiples are 12.8x and 1.5x.
| P/S Ratio | 12.8x |
|---|---|
| Forward P/S | 6.7x |
| P/B Ratio | 1.5x |
| P/TBV Ratio | 1.6x |
Price Statistics
The stock is down 73.71% over 52 weeks and trades 18.75% above its 50-day average.
| Beta (1Y) | 0.80 |
|---|---|
| 52-Week Change | -73.71% |
| 1-Month Change | +60.77% |
| 3-Month Change | -63.68% |
| 6-Month Change | -51.73% |
| 5-Year Change | -96.24% |
| Total Return (1Y) | -73.71% |
| Total Return (3Y CAGR) | -40.30% |
| Total Return (5Y CAGR) | -45.44% |
| Return vs SPY (1Y) | -85.02% |
| Max Drawdown (1Y) | -87.06% |
| Max Drawdown (3Y) | -97.23% |
| Sharpe Ratio (1Y) | -0.98 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $3.52 |
| 200-Day Average | $8.51 |
| 52-Week Range | $2.43 to $21.60 |
| RSI (14 Days) | 52.8 |
| Average Volume (20 Days) | 26.29K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.60x current liabilities.
| Current Ratio | 10.60x |
|---|---|
| Quick Ratio | 10.60x |
Returns and Efficiency
Return on equity is -163.18% and return on assets is -161.71% over the last 12 months.
| Return on Equity (ROE) | -163.18% |
|---|---|
| Return on Assets (ROA) | -161.71% |
| Return on Capital Employed (ROCE) | -175.90% |
| Asset Turnover | 0.03x |
| Receivables Turnover | 11.91x |
Scores
LEXX has an Altman Z-Score of -14.87, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -14.87 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $194.00K over the last 12 months is down 68.50% from the 12 months before.
| Revenue | $194.00K |
|---|---|
| Revenue Growth (YoY) | -68.50% |
| Gross Profit | $169.80K |
| Operating Income | -$7.71M |
| Pretax Income | -$7.74M |
| Net Income | -$7.73M |
| EBITDA | -$7.66M |
| EBIT | -$7.74M |
| Reported EPS (TTM) | -$5.25 |
Trailing 12 months through May 31, 2026.
Balance Sheet
Shareholder equity funds 99.16% of the $4.78M in total assets.
| Cash and Equivalents | $3.48M |
|---|---|
| Working Capital | $3.68M |
| Shareholder Equity | $4.74M |
| Book Value Per Share | $2.87 |
| Tangible Book Value | $4.40M |
| Tangible Book Per Share | $2.66 |
| Total Assets | $4.78M |
| Total Liabilities | $437.09K |
Balance sheet as of May 31, 2026.
Cash Flow
After $101.87K of capital spending, operating cash flow left -$7.53M of free cash flow.
| Operating Cash Flow | -$7.43M |
|---|---|
| Capital Expenditures | $101.87K |
| Free Cash Flow | -$7.53M |
| FCF Per Share | -$3.57 |
| Depreciation and Amortization | $76.57K |
Trailing 12 months through May 31, 2026.
Margins
The operating margin is -3973.16%.
| Gross Margin | 87.53% |
|---|---|
| Operating Margin | -3973.16% |
| Pretax Margin | -3987.65% |
| Net Margin | -3985.58% |
| EBITDA Margin | -3948.18% |
| EBIT Margin | -3987.65% |
| FCF Margin | -3880.08% |
| Gross Margin (5Y Average) | 86.45% |
Growth
Revenue grew 40.34% a year over 3 years.
| Revenue Growth (3Y CAGR) | +40.34% |
|---|---|
| Revenue Growth (5Y CAGR) | +12.92% |
| Book Value Per Share Growth (2Y CAGR) | -42.37% |
| Tangible Book Per Share Growth (2Y CAGR) | -40.73% |
Dividends and Yields
LEXX does not pay a dividend. Its free cash flow yield is -108.89%.
| FCF Yield | -108.89% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-15 reverse split on Aug 3, 2026.
| Last Split Date | Aug 3, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About LEXX
What is LEXX's market cap?
Lexaria Bioscience has a market cap of $9.35M.
How many shares of LEXX are outstanding?
Lexaria Bioscience has 1.65M shares outstanding. The count is up 35.56% from a year earlier.
Does LEXX pay a dividend?
No. Lexaria Bioscience does not pay a dividend.
LEXX pages: Overview, Charting, Earnings, Financials, Statistics